$EYPT (+5.5% pre) EyePoint Pharmaceuticals (EYPT) Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - SI   https://t.co/QezDH9RekQ